{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"36","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The median amount of time from the end of treatment until to distant recurrence. Distant recurrence is when cancer spreads to areas in the body away from the primary cancer site.","dispersionType":"Full Range","groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"OG000","title":"Experimental: Bevacizumab, Radiation, and Surgery"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 years","title":"Disease Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}